Remdesivir for COVID-19

On May 1, 2020, the FDA authorized the emergency use of Remdesivir for COVID-19. This was based on a preliminary analysis of an NIH clinical trial. However, information is still lacking on safety and efficacy in a larger study population. In this session, we will review the known mechanism of action of this novel antiviral medication and limitations of data.